INSIGHTS ON DRUG DEVELOPMENT

• Labs In The 21st Century – Accelerating Innovation

  Labs in the 21st century are not working anymore like in the past. Workflows are digital and connected, environments are harmonized and standardized as well as lab scientists are collaborating across borders. This requires an intelligent scientific platform that is aware of the context in which they operate. In this webinar, we will discuss how an intelligent scientific platform for the lab can accelerate innovation, leverage marketplaces and allow the labs of the 21st century to move to new horizons for lab innovation and efficiency.

• Crystallization Process Development: Peptide Crystallization

  Whether performed during formation of an API or as a means to purify intermediates, achieving control of nucleation and crystal growth is critical to designing a successful peptide crystallization process.

• Taste Masking Solutions For Pediatric Populations

  Originally presented by Srinivasan Shanmugam, Senior Director Pharmaceutical Sciences, this slideshow reviews the pediatric population and their needs, the significance of taste masking, and taste masking strategies.

• Nucleases - Are They A Problem For NAB Nanosep® Centrifugal Devices?

  We examine whether the sample tubes and collection tubes of the NAB Nanosep centrifugal devices contain detectable amounts of DNase or RNase.

• MIGAL Accelerates COVID-19 Vaccine Development With BIOVIA Discovery Studio And Pipeline Pilot

  11/24/2021

  When COVID-19 became a pandemic, scientists at the Migal Galilee Research Institute in Israel – an academic research and development center – began using applications and computational tools to apply its research to the study of COVID-19 mutations. Watch the video to learn how they used these tools to accelerate their research and development of a possible vaccine against SARS-CoV-2.  

• Imaging Large Volume Subcutaneous Injections In Swine and Human Models Informs Effective Clinical Design

  1/19/2022

  New higher volume, higher viscosity pharmaceutical formulations for subcutaneous injection, alternatives to traditional intravenous treatment, enable chronic disease therapy in alternate settings.

• 4Cell®BHK-21 CD Medium - Adaptation Of BHK-21 Cells To Suspension Using Chemically Defined Medium

  4/9/2021

  BHK-21 cell strains have been utilized for several years as a platform for veterinary vaccines and recombinant protein manufacturing. However, these cells are anchorage-dependent, requiring the use of dissociation agents that slow and are traumatic for cells while also creating scale-up limitations. In this study, we successfully adapted anchorage serum-dependent BHK-21 cells to suspension in a chemically defined (CD), serum-free, Sartorius medium.

• Innovating For The Future: Accelerating The Arrival Of Immuno-Oncology 2.0

  4/4/2022

  Read how by enabling the delivery of solutions in specific areas, the new era of manufacturing can begin, and the next generation of cell-based immunotherapies can reach patients.

• Development And Qualification Of A Complex Potency ELISA

  4/8/2021

  PD-1 has an important role in preventing autoimmune diseases but can also prevent the immune system from killing cancer cells. PD-1, which can be found on T cells and some B cells, normally interacts with its two ligands PD-L1 and PD-L2, found on antigen-presenting cells and tumor cells. Many new therapies are targeting the PD-1 pathway to boost the immune response to cancer cells. Current assays used to measure the activity of anti-PD-1 or anti-PD-L1 antibodies can be highly variable due to their reliance on primary cells and complex assay protocols. One method to demonstrate the activity of anti PD-1 molecules using a functionally relevant but less variable method is using a potency ELISA.